Publicaciones (311) Publicaciones de Domingo Andres Pascual Figal

2023

  1. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome

    GeroScience, Vol. 45, Núm. 2, pp. 1231-1236

  2. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  3. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  4. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  5. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study

    Journal of Cardiac Failure

  6. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  7. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 389-398

  8. Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients

    IJC Heart and Vasculature, Vol. 46

  9. Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 80-89

  10. Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

    European heart journal

  11. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  12. Personalizing anti-inflammatory therapy in heart failure: A new way

    European Journal of Heart Failure

  13. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

    The Lancet, Vol. 402, Núm. 10396, pp. 118-128